Corcept Therapeutics (CORT) to Release Earnings on Thursday

Corcept Therapeutics (NASDAQ:CORT) is anticipated to issue its quarterly earnings data after the market closes on Thursday, February 20th. Analysts expect the company to announce earnings of $0.37 per share and revenue of $200.12 million for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

Corcept Therapeutics Stock Performance

Shares of CORT opened at $72.60 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70. The company has a market capitalization of $7.61 billion, a price-to-earnings ratio of 57.62 and a beta of 0.58. Corcept Therapeutics has a 1 year low of $20.84 and a 1 year high of $74.61. The company’s 50 day simple moving average is $58.24 and its 200 day simple moving average is $49.72.

Insider Activity at Corcept Therapeutics

In other news, insider Joseph Douglas Lyon sold 1,411 shares of Corcept Therapeutics stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $56.72, for a total value of $80,031.92. Following the completion of the transaction, the insider now directly owns 8,494 shares of the company’s stock, valued at approximately $481,779.68. The trade was a 14.25 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Sean Maduck sold 20,000 shares of Corcept Therapeutics stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total transaction of $1,007,800.00. Following the completion of the transaction, the insider now directly owns 85,318 shares of the company’s stock, valued at $4,299,174.02. This trade represents a 18.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 28,011 shares of company stock valued at $1,479,608. Corporate insiders own 20.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on CORT shares. Canaccord Genuity Group raised their target price on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, January 30th. StockNews.com downgraded shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 25th. Finally, HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Corcept Therapeutics in a research note on Friday, February 7th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $88.25.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.